UPDATED: Another three biotechs are set to debut on Nasdaq as combined industry raise tops $14B
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
Despite an IPO slowdown in the third quarter, it’s becoming apparent that Q4 will again see an active biotech market barely a week into October.
Two more companies priced their initial public offerings late Thursday night in Pyxis Oncology and IsoPlexis. Pyxis led the way by launching at $16 per share and with a $168 million raise, while IsoPlexis followed up with a $15 debut and $125 million in IPO cash.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.